Table 2. Summary of adverse events.
| Systemic
agent |
SAE incidence
rate per patient week (%) |
AE incidence rate per
patient week (%) |
Common AEs (clinical trial incidence of ≥1/100) |
|---|---|---|---|
| Ciclosporin | 0–2.2 | 0–20.8 | Serum creatinine increase, hypertension, GI upset, infections, skin
infections, headache, fatigue, cramps, paraesthesia, lower limb oedema, hypertrichosis, gingival hyperplasia, anaemia, leukopenia, pancytopenia, thrombocytopenia, ESR increase, liver enzyme increase, magnesium decrease, fever, malaise, AD exacerbation, dyslipidaemia, tremor, flushing, metallic taste |
| Methotrexate | 0.19 | 9.8–23.5 | GI upset, infections, liver enzyme increase, skin infections, AD
exacerbation, anaemia, leukopenia, pancytopenia, fatigue, headache, renal impairment, fever, malaise |
| Azathioprine | 0.03 | 3–22.9 | GI upset, URTI, LRTI, fatigue, light-headedness, malaise, headache,
folliculitis, skin infections, lymphopenia, neutropenia, liver enzyme increase, AD exacerbation |
| Mycophenolate
mofetil |
0 | 4.2 | Nausea, headache, fatigue, paraesthesia, muscle ache, infections,
serum creatinine increase, leukopenia, liver enzyme increase, magnesium decrease |
| Dupilumab | 0–0.55 | 6.4–21.6 | Nasopharyngitis, headache, URTI, injection site reactions,
conjunctivitis, AD exacerbation, skin infections, herpes viral infections |
| Nemolizumab | 0.18 | 6.6 | Nasopharyngitis, AD exacerbation, serum CK increase, URTI,
headache, peripheral oedema, impetigo, injection-site reactions |
| Ustekinumab | 0 | 2.3–2.4 | Nasopharyngitis, AD exacerbation |
| Fezakinumab | 0.42 | 2.25 | Viral URTI |
| Lebrikizumab | Not reported
(3.2% of patients had ≥1 SAE over 20-week study) |
Not reported
(67% of patients had ≥1 AE over 20-week study) |
Infections, skin infections, HSV and HZV infections,
conjunctivitis, injection site reactions |
| Baricitinib | 0.08% | Not reported
(59% of patients had ≥1 AE over 16-week study) |
Headache, serum CK increase, AD exacerbation, nasopharyngitis,
cellulitis, infections |
| Tralokinumab | Not reported
(3.3% of patients had ≥1 SAE over 12-week study) |
Not reported
(66% of patients had ≥1 AE over 12-week study) |
Nasopharyngitis, URTI, headache, AD exacerbation, injection site
reactions, arthralgia, syncope |
AD, atopic dermatitis; AE, adverse event; CK, creatine kinase; ESR, erythrocyte sedimentation rate; GI, gastrointestinal; HSV, herpes simplex virus; HZV, herpes zoster virus; LRTI, lower respiratory tract infection; SAE, serious adverse event; URTI, upper respiratory tract infection.